← Back to Search

Interferon

Interferon Alfa-2A in Cancer Participants for Kidney Cancer

Phase 2 & 3
Waitlist Available
Research Sponsored by Hoffmann-La Roche
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline up to approximately 3 years
Awards & highlights
No Placebo-Only Group

Summary

This open label extension study will give an opportunity to the participants that have responded to the treatment with Pegylated-Interferon Alfa-2a (Pegasys) or Recombinant Interferon Alfa-2a (Roferon-A®) in prior clinical studies NO15753 (NCT00003542) for Renal Cell Carcinoma (RCC), NO15764 (NCT number not available) and NO16006 (NCT02736721) for Chronic Myelogenous Leukemia (CML), and NO16007 (NCT number not available) for Malignant Melanoma (MM).

Eligible Conditions
  • Kidney Cancer
  • Leukemia
  • Melanoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to approximately 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline up to approximately 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants With Serious Adverse Events (SAEs)
Secondary study objectives
Number of Participants With Overall Tumor Response

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Interferon Alfa-2A in Cancer ParticipantsExperimental Treatment2 Interventions
Participants who responded to interferon alfa-2A (either pegylated interferon alfa-2A or recombinant interferon alfa 2A) treatment during the parent study will continue to receive the same treatment in this study. Pegylated interferon alfa-2A will be administered subcutaneously once weekly and recombinant interferon alfa 2A will be administered subcutaneously once daily, until disease progression, withdrawal, or death whichever occurs first (up to approximately 3 years).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Peginterferon alfa-2a
FDA approved
Interferon alfa-2a
FDA approved

Find a Location

Who is running the clinical trial?

Hoffmann-La RocheLead Sponsor
2,456 Previous Clinical Trials
1,097,633 Total Patients Enrolled
Clinical TrialsStudy ChairHoffmann-La Roche
2,225 Previous Clinical Trials
896,381 Total Patients Enrolled
~0 spots leftby Nov 2025